The Essure system is usually inserted by visualizing the fallopian tubes using a hysteroscope — a thin tube equipped with a camera lens — as an outpatient procedure. The procedure typically takes 30 minutes or less. You may be given medication before the procedure to minimize spasm of your fallopian tubes and reduce pain from the procedure.
During the procedure
Your health care provider will insert a hysteroscope through your vagina and cervix into your uterus and check to make sure both fallopian tube openings are accessible. Using a small catheter attached to the hysteroscope, your health care provider will place tiny coils inside your fallopian tubes.
After the procedure
You may be allowed to go home immediately after the procedure and return to your normal activities the same day. Side effects may include:
- Abdominal pain
- Nausea or vomiting
- Dizziness or lightheadedness
- Bleeding or spotting
Contact your health care provider immediately if:
- You have severe or persistent pelvic pain
- You pass a coil
During the three months following the procedure, you must use another method of contraception. After three months, you will have an X-ray (hysterosalpingography) or an ultrasound to confirm the correct placement of the Essure system and verify that your fallopian tubes are blocked. If the procedure is successful, you can stop using other forms of birth control at this point.
If you think you're pregnant at any time after the procedure, contact your health care provider immediately. The Essure system doesn't affect your menstrual cycle.
The Essure system isn't reversible. Couples who want to try in vitro fertilization need to be aware that a portion of the coil protrudes into the uterine cavity. Because of this, the Essure system may interfere with the success of in vitro fertilization (IVF).
Jan. 16, 2018
- Hatcher RA, et al. Contraceptive Technology. 20th ed. New York, N.Y.: Ardent Media; 2011:249.
- Greenberg J. Hysteroscopic sterilization. http://www.uptodate.com/home. Accessed Oct. 26, 2014.
- Essure (prescribing information). Milipitus, Calif.: Bayer Healthcare LLC; 2012. http://www.essuremd.com. Accessed Oct. 28, 2014.
- Adelman MR, et al. Management of complications encountered with Essure hysteroscopic sterilization: A systematic review. Journal of Minimally Invasive Gynecology. 2014;21:733.
- Jost S, et al. Essure permanent birth control effectiveness: A seven-year survey. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013;168:134.
- FDA takes additional action to better understand safety of Essure, inform patients of potential risks. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm488313.htm. Accessed March 3, 2016.
- Laughlin-Tommaso SK (expert opinion). Mayo Clinic, Rochester, Minn. March 4, 2016.
- Essure permanent birth control system by Bayer Healthcare: FDA announcement — label changes. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm529241.htm. Accessed Nov. 16, 2016.